H., Kasper, S., Lake, J.,
It is associated with an 82.4% reduction in liver fat and normalisation in 86% of cases with a weekly 12 mg dose over 24 weeks, in relation to visceral adipose tissue reduction, improved insulin sensitivity, decreased leptin levels, increased adiponectin, and favourable changes in lipid metabolism parameters and fibrosis markers such as Pro-C3.56 Amylin analogues in combination with GLP-1 receptor agonists: CagriSema Amylin is a 37-amino-acid peptide that is co-secreted with insulin by pancreatic beta cells.57 It shares structural similarity with peptides of the calcitonin family
Long-term safety is unknown
JCI Insight 6 , e148003 (2021)
Lead with protein and fiber
Do GLP-1 therapies replace lifestyle counseling